What is CBIO's current stock price?

CBIO (Crescent Biopharma, Inc.) is currently trading at $20.74 with a market cap of $571.8M.

What sector is Crescent Biopharma, Inc. in?

Crescent Biopharma, Inc. (CBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CBIO a good stock to buy?

Analysts have a Buy consensus on CBIO with a price target of $33.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CBIO Crescent Biopharma, Inc.

Healthcare

$20.74+2.52%ClosedMarket Cap: $571.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.43

P/S

48.12

EV/EBITDA

-2.42

DCF Value

$20.86

FCF Yield

-26.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

-1372.9%

Net Margin

-1363.9%

ROE

-100.9%

ROA

-81.4%

ROIC

-88.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$1.0M	$-23.3M	$—
Q4 null	$10.8M	$-92.4M	$—
FY null	$10.8M	$-153.9M	$—
Q3 null	$0.00	$-24.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$33.00

Target (Median)

$35.00

Target Range

$29.00 - $35.00

1 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-02

HC Wainwright & Co.Buy

2025-08-27

Trading Activity

Insider Trades

View All

Scalzo Richard Williamofficer: Chief Financial Officer

SellWed Dec 17

Pinkas Janofficer: Chief Scientific Officer

SellWed Dec 17

Pinkas Janofficer: Chief Scientific Officer

SellWed Dec 17

Pinkas Janofficer: Chief Scientific Officer

SellWed Dec 17

Doughty Christopher Grantofficer: Chief Business Officer

SellWed Dec 17

Latest News

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual MeetingGlobeNewsWire · Thu May 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.20

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.

Peers